Adverum Biotechnologies Reports Positive 24-Week Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy to Treat Wet AMD

September 12, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search